

## Grifols achieves its highest-ever score in the 2024 S&P Global Sustainability Assessment

- *The company's 70 points in the 2024 S&P Global Corporate Sustainability Assessment (CSA) reflects an improvement of seven points over last year's results*
- *S&P highlights Grifols' commitment to human rights, supply chain management, climate change management and health & safety*

**Barcelona, Spain, October 15, 2024** – Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announced that it has achieved its highest-ever S&P Global ESG score. The company's rating of 70 points marks a seven-point increase over last year's results and highlights the company's significant progress and unwavering commitment to sustainability.

In terms of governance, S&P has acknowledged Grifols' efforts to foster a more responsible and sustainable supply chain. Additionally, the company continues to earn the highest score for its sustainability reporting and business ethics.

Regarding its environmental approach, Grifols has set more ambitious targets to accelerate its transition to a low-carbon economy. S&P has recognized Grifols' progress in climate strategy, while maintaining the highest score in climate governance and risk management.

With respect to the social strategy, S&P has rewarded Grifols' commitment to ensuring a safe and healthy workplace for all employees, as well as its continued dedication to upholding and promoting human rights across all areas of operation. In addition, S&P has once again awarded the company the highest possible score for its commitment to ethical marketing.

This achievement underscores Grifols' unwavering commitment to excellence in environmental, social and governance practices. As the company continues to advance its sustainability goals, it remains focused on driving long-term value and making a lasting impact toward a more sustainable, ethical and resilient future for all stakeholders.

For more information on Grifols' ESG initiatives and progress, please visit [Sustainability | Grifols](#) and read more about the company's commitment in the [Biopharmaceutical Industry Sustainability Reports | Grifols](#).

---

### INVESTORS:

**Grifols Investors Relations & Sustainability**  
[inversores@grifols.com](mailto:inversores@grifols.com) - [investors@grifols.com](mailto:investors@grifols.com)

# GRIFOLS

[sostenibilidad@rifols.com](mailto:sostenibilidad@rifols.com) – [sustainability@grifols.com](mailto:sustainability@grifols.com)

Tel.: +34 93 571 02 21

## MEDIA CONTACTS:

### Grifols Press Office

[media@grifols.com](mailto:media@grifols.com)

Tel. +34 93 571 00 02

### Spain

Duomo Comunicación

Tel.: +34 91 311 92 89 – 91 311 92 90

Raquel Lumbreras

[raquel\\_lumbreras@duomocomunicacion.com](mailto:raquel_lumbreras@duomocomunicacion.com)

Tel.: +34 659 57 21 85

Borja Gómez

[borja\\_gomez@duomocomunicacion.com](mailto:borja_gomez@duomocomunicacion.com)

Tel.: 650 40 22 25

## About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces, and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology, and infectious diseases.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with over 390 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 23,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety, and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS). For more information about Grifols, please visit [www.grifols.com](http://www.grifols.com)



## **LEGAL DISCLAIMER**

The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.